Serum-DNA Methylation Patterns Might Allow Early Identification of Breast, Ovarian Cancer Serum-DNA Methylation Patterns Might Allow Early Identification of Breast, Ovarian Cancer
Methylation patterns in serum DNA might allow for the early identification of disseminated breast cancer and ovarian cancer, according to two new reports from the U.K.Reuters Health Information
ConclusionAll women in breast or breast/ovarian cancer kindreds would benefit from being offered genetic testing irrespective of which causative genetic variants have been demonstrated in their relatives.
This article is protected by copyright. All rights reserved.
ConclusionFor ER-positive premenopausal patients, the sequential use of GnRHa and chemotherapy showed ovarian preservation and survival outcomes that were no worse than simultaneous use. The application of GnRHa can probably be delayed until menstruation resumption after chemotherapy.
BRCA mutations are inherited and increase the risk of breast and ovarian cancers. Between 45 percent and 90 percent of women with a BRCA mutation develop breast cancer, compared with about 12.5 percent of women in the general population.
The Food and Drug Administration on Friday cleared the first treatment for patients with advanced breast cancer caused by BRCA mutations, which are genetic defects that raise the risk of malignancies. The drug, called Lynparza, already is approved for certain patients with advanced ovarian cancer associated with the same mutations. Richard Pazdur, director of the […]Related:FDA warns against giving kids cough and cold medicines with codeine or hydrocodoneNew study on abortion pill shows high success, low rate of complicationsHe was 21 and fit. He tried to push through the flu — and it killed him.
Estrogen is a miracle drug for many women who experience the drenching sweats, sexual dysfunction and frustrating brain betrayals associated with entering menopause. It comes in expensive patches, less expensive pills or injections, as well as vaginal creams or rings. It has gone in and out of favor with the medical community for decades. Estrogen is the main ingredient in most birth control pills and has been studied extensively in that context as well as in the setting of women whose ovaries have ceased to produce it as they age. It can increase the risk of migraines, blood clots in the legs or lungs; it can cause benign...
Conclusion: These results provide the actual percentage of family or personal history of cancer that can be attributed to pathogenic or likely pathogenic variants in one or more of the genes on our panel and corroborate the utility of multi-gene panels over sequential testing to identify individuals with an inherited predisposition to cancer. PMID: 29308099 [PubMed]
Abstract A strong positive association has been observed between circulating anti‐Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important because of the paucity of biomarkers of breast cancer risk in premenopausal women. We conducted a consortium study including ten prospective cohorts that had collected blood from premenopausal women. A nested case‐control design was implemented within each cohort. A total of 2,835 invasive (80%) and in situ (20%) breast cancer cases were individually matched to controls (n = 3,122) on ...
ConclusionAll variants with a change in classification in our cohort were down-staged towards no clinical significance by a panel of experts of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Prevention in families with Class 3 variants should be based on pedigree based risks and should not be guided by the presence of a VUS.
ConclusionMore than 60% of women undergoing RRS were BRCAm negative or untested. Counselling of high-risk women without defined germline mutations remains a challenge for gynaecologists because the likelihood of removing STIC lesions or occult invasive cancer is low. Removal of coincidental pathology may give added value to RRS in these women.